Acadia Pharmaceuticals | ACAD - Sales Revenues


Acadia Pharmaceuticals reported $284M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
Acadia Pharmaceuticals USD 284M 5.4M Dec/2025
ALKERMES USD 384.5M 9.7M Dec/2025
Alnylam Pharmaceuticals USD 1.1B 150M Dec/2025
Biogen USD 2.28B 250M Dec/2025
BioMarin Pharmaceutical USD 875M 99M Dec/2025
Bristol-Myers Squibb USD 12.5B 300M Dec/2025
Cara Therapeutics USD 2.57M 1.11M Mar/2025
Corcept Therapeutics USD 202.12M 5.48M Dec/2025
Cytokinetics USD 17.76M 15.83M Dec/2025
Eisai JPY 219.94B 22.58B Dec/2025
Eli Lilly USD 19.3B 1.7B Dec/2025
Incyte USD 1.51B 140M Dec/2025
J&J USD 24.1B 500M Mar/2026
Moderna USD 678M 342M Dec/2025
Neurocrine Biosciences USD 805.5M 10.6M Dec/2025
Pfizer USD 17.58B 880M Dec/2025
Prothena USD 21K 2.4M Dec/2025
PTC Therapeutics USD 164.7M 46.3M Dec/2025
Sarepta Therapeutics USD 442.9M 43.5M Dec/2025
Ultragenyx Pharmaceutical USD 207M 47M Dec/2025
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024
Vertex Pharmaceuticals USD 3.19B 110M Dec/2025